drugset / Trial / NCT05999240
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
Phase 2
Recruiting
30 enrolled
New York State Psychiatric Institute
ACADIA Pharmaceuticals Inc. · collabResearch Foundation for Mental Hygiene, Inc. · collabUniversity of Kansas Medical Center · collabWeill Medical College of Cornell University · collab
RandomizedCrossoverTriple-blindTreatment
Summary
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 12 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |